FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies

Affiliations

• ¹ Clinical Hematology, Nantes University Hospital, Nantes, France; CRCI2NA UMR INSERM 1307CNRS 6075 - Nantes Université - Angers University, Nantes. [email protected].
• ² CRCI2NA UMR INSERM 1307CNRS 6075 - Nantes Université - Angers University, Nantes.
• ³ Clinical Hematology, Limoges University Hospital, Limoges.
• ⁴ Clinical Hematology, Bordeaux University Hospital Haut-Lévêque, Pessac.
• ⁵ Clinical Hematology, Angers University Hospital, Angers.
• ⁶ Clinical Hematology, Besançon University Hospital, Besançon.
• ⁷ Clinical Hematology, Grenoble University Hospital, Grenoble.
• ⁸ Clinical Hematology, Institut Paoli Calmettes, Marseille.
• ⁹ Clinical Hematology, Nice University Hospital, Nice.
• ¹⁰ Clinical Hematology, Poitiers University Hospital, Poitiers.
• ¹¹ Clinical Hematology, Saint Louis Hospital, Paris.
• ¹² Groupe Francophone des Myélodysplasies, Paris.
• ¹³ Clinical Hematology, Nantes University Hospital, Nantes, France; CRCI2NA UMR INSERM 1307CNRS 6075 - Nantes Université - Angers University, Nantes.